Ultragenyx has agreed to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million, the company said, tying the voucher to FDA approval of its one-time gene therapy GENGLYCOS (pariglasgene brecaparvovec-opnr; DTX401). The transaction is subject to customary closing conditions including the Hart-Scott-Rodino waiting period.